Apellis takes the complement fight to Astrazeneca
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
A new setting for antigen testing
It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.
Covid-19 vaccine developers remind the world that setbacks happen
As Biontech and Pfizer’s Covid-19 vaccine gets a positive US vote, delays for Sanofi, Glaxo and CSL show that top-speed drug development is the exception.
Astrazeneca’s vaccine looks increasingly like an also-ran
Yesterday’s analysis of data on Astra's Covid-19 vaccine suggests it might remain a non-Western option.
